STAT
verified

Discover in-depth analysis of biopharma and the life sciences. Reporting from the frontiers of health & medicine. Sign up for any of our 10 free newsletters here: http://statnews.com/signup

@STATnews@flipboard.com

STAT
flipped into STAT's HOMEPAGE
12 hours ago
Up and down the ladder: The latest comings and goings
STAT - Ed Silverman
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with …
STAT
flipped into The top headlines in pharma
13 hours ago
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
STAT - Meghana Keshavan
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We have some news out of a …
STAT
flipped into STAT's HOMEPAGE
14 hours ago
At a federal autism advisory committee meeting, members double down on long-debunked theories
STAT - O. Rose Broderick
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Still not over Dolly Parton’s …
STAT
flipped into The top headlines in pharma
14 hours ago
Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more
STAT - Ed Silverman
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about …
STAT
flipped into STAT's HOMEPAGE
17 hours ago
Cytokinetics details trial win for what could be its next approval
STAT - Andrew Joseph
It took Cytokinetics 27 years to win its first regulatory approval. The second one could happen much faster than that. The biotech on Friday unveiled …
STAT
flipped into The top headlines in pharma
18 hours ago
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
STAT - Andrew Joseph
AstraZeneca on Friday detailed the surprise failure of a closely watched heart disease clinical trial, laying out how its experimental drug offered …